Key Considerations When Selecting EGFR Inhibitor Treatments in NSCLC - Episode 9
Final Thoughts on the Treatment of EGFR-Mutant NSCLC: Balancing Safety and Efficacy, and the Importance of Incorporating Supportive Care Strategies
Panelists discuss how implementing the new standard of combination therapies requires thorough patient education, prophylactic management of toxicities, and multidisciplinary support to optimize outcomes for patients with EGFR-mutant lung cancer.
Video Player is loading.
Video content above is prompted by the following:
Closing Thoughts and Key Take-Home Messages
Key Themes:
- New Standard of Care: Both experts agree combinations represent the new standard for most patients
- Toxicity Management: Critical importance of prophylactic approaches, particularly for amivantamab-based regimens
- Patient Education: Need for thorough patient education and support through treatment
Notable Insights:
- Dr Dietrich: Emphasized the need to “get really good at managing on-target toxicity” and “implementing prophylactic measures about forming networks with dermatology and other specialties.” He acknowledged that “we have an affinity to a single agent or osimertinib, but I think we have to just face reality, that this relatively easy one-size-fits-all option doesn’t meet 2025 expectations anymore.”
- Dr Piotrowska: Highlighted specific prophylactic approaches, including “dexamethasone premedications to prevent infusion reactions, the dermatologic prophylaxis, which includes a tetracycline antibiotic for the first 12 weeks” and “[venous thromboembolism] prophylaxis... recommended for the first 4 months of treatment” with amivantamab plus lazertinib.
Related Content:
